Ciana Home - Ciana Therapeutics

Loading...

Protecting the
Gift of Sight

Developing a front-line treatment to combat
vision loss and blindness in diabetes

Learn more
Protecting the
Gift of Sight

Developing a front-line treatment to combat
vision loss and blindness in diabetes

Learn more
Protecting the
Gift of Sight

Developing a front-line treatment to combat
vision loss and blindness in diabetes

Learn more

Ciana Homelyhneogco2020-10-05T09:32:19+00:00

Who We Are

Ciana Therapeutics is a clinical development-stage company led by an experienced team developing new therapies within ophthalmology and with an initial focus on Diabetic Retinopathy.

Unmet Need

More than 463 million patients are living with diabetes. A serious complication of diabetes is Diabetic Retinopathy.

Diabetic Retinopathy damages the eyes in patients with diabetes and can lead to vision loss and blindness. This eye complication afflicts 125 million patients with diabetes globally – and 30 million people in the US and Europe alone.

Novel Approach

Ciana’s therapy is based on Danegaptide – a drug that can both treat Diabetic Retinopathy and prevent disease progression.

Unlike the leading injectable eye therapies that only block VEGF and limit vascular edema, Danegaptide can stabilize cell-cell junctions in the retinal capillaries, protect from capillary loss, and prevent vascular leakage and edema.

Facts on Diabetic Retinopathy

Better treatments are needed to prevent vision loss and blindness

Growing Problem

Global prevalence of diabetes is 463 million, growing to 700 million by 2045

Vision Loss

30% of diabetes patients with Type 1 and 2 have DR and 5% progress to permeant vision loss

Cause Of Blindness

Diabetic Retinopathy is the leading cause of blindness in working age adults

Early Symptoms

No early symptoms of Diabetic Retinopathy – screening used to detect disease

Late Therapies

Current therapies are used late in the course of disease when vision loss has already occurred with limited efficacy

Facts on Diabetic Retinopathy

Better treatments are needed to prevent vision loss and blindness

Growing Problem

Global prevalence of diabetes is 463 million, growing to 700 million by 2045

Vision Loss

30% of diabetes patients with Type 1 and 2 have DR and 5% progress to permeant vision loss

Cause Of Blindness

Diabetic Retinopathy is the leading cause of blindness in working age adults

Early Symptoms

No early symptoms of Diabetic Retinopathy – screening used to detect disease

Late Therapies

Current therapies are used late in the course of disease when vision loss has already occurred with limited efficacy

Facts on Diabetic Retinopathy

Better treatments are needed to prevent vision loss and blindness

Growing Problem

Global prevalence of diabetes is 463 million, growing to 700 million by 2045

Vision Loss

30% of diabetes patients with Type 1 and 2 have DR and 5% progress to permeant vision loss

Cause Of Blindness

Diabetic Retinopathy is the leading cause of blindness in working age adults

Early Symptoms

No early symptoms of Diabetic Retinopathy – screening used to detect disease

Late Therapies

Current therapies are used late in the course of disease when vision loss has already occurred with limited efficacy

Patient Focused

Combatting vision loss and blindness in patients with diabetes

Normal

Diabetic Retinopathy

Normal

Diabetic Macular Edema

Drag bar

: See Normal versus Disease

Work with us

Developing a front-line treatment to combat vision loss and blindness in diabetes